TDP-43 pathology in a patient carrying G2019S LRRK2mutation and a novel p.Q124E MAPT

Neurobiology of Aging

Volumn 34, Issue 12, 2013, Pages 2889.e5-2889.e9

  Ling, Helen ^a   Kara, Eleanna ^a   Bandopadhyay, Rina ^a   Hardy, John ^a   Holton, Janice ^a   Xiromerisiou, Georgia ^a   Lees, Andrew ^a   Houlden, Henry ^a   Revesz, Tamas ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

LRRK2; MAPT; Parkinson's disease; Tau; TDP 43

Indexed keywords

GENOMIC DNA; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PROTEIN ANTIBODY; TAR DNA BINDING PROTEIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CASE REPORT; CLINICAL FEATURE; COHORT ANALYSIS; CORPUS STRIATUM; DEGENERATIVE DISEASE; EXON; FEMALE; GENE; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOTE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEWY BODY; LRRK2 GENE; MAPT GENE; NEOCORTEX; NEUROPATHOLOGY; NIGRAL DEGENERATION; NUCLEOTIDE SEQUENCE; PARKINSONISM; PRIORITY JOURNAL; SUBSTANTIA NIGRA PARS COMPACTA; TDP 43 PROTEINOPATHY; TREATMENT RESPONSE;

LRRK2; MAPT; PARKINSON'S DISEASE; TAU; TDP-43;

AGED; AGED, 80 AND OVER; BRAIN; DNA-BINDING PROTEINS; EXONS; FEMALE; FRONTOTEMPORAL LOBAR DEGENERATION; HETEROZYGOTE; HUMANS; LEWY BODIES; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; TAU PROTEINS;

EID: 84884150340     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.04.011     Document Type: Article

References (47)

1. Amador-Ortiz C., Lin W.L., Ahmed Z., Personett D., Davies P., Duara R., Graff-Radford N.R., Hutton M.L., Dickson D.W. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann. Neurol. 2007, 61:435-445.
2. Arai T., Mackenzie I.R., Hasegawa M., Nonoka T., Niizato K., Tsuchiya K., Iritani S., Onaya M., Akiyama H. Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol. 2009, 117:125-136.
3. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006, 112:389-404.
4. Burns J.M., Galvin J.E., Roe C.M., Morris J.C., McKeel D.W. The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs. Neurology 2005, 64:1397-1403.
5. Coppola G., Chinnathambi S., Lee J.J., Dombroski B.A., Baker M.C., Soto-Ortolaza A.I., Lee S.E., Klein E., Huang A.Y., Sears R., Lane J.R., Karydas A.M., Kenet R.O., Biernat J., Wang L.S., Cotman C.W., Decarli C.S., Levey A.I., Ringman J.M., Mendez M.F., Chui H.C., Le Ber I., Brice A., Lupton M.K., Preza E., Lovestone S., Powell J., Graff-Radford N., Petersen R.C., Boeve B.F., Lippa C.F., Bigio E.H., Mackenzie I., Finger E., Kertesz A., Caselli R.J., Gearing M., Juncos J.L., Ghetti B., Spina S., Bordelon Y.M., Tourtellotte W.W., Frosch M.P., Vonsattel J.P., Zarow C., Beach T.G., Albin R.L., Lieberman A.P., Lee V.M., Trojanowski J.Q., Van Deerlin V.M., Bird T.D., Galasko D.R., Masliah E., White C.L., Troncoso J.C., Hannequin D., Boxer A.L., Geschwind M.D., Kumar S., Mandelkow E.M., Wszolek Z.K., Uitti R.J., Dickson D.W., Haines J.L., Mayeux R., Pericak-Vance M.A., Farrer L.A., Ross O.A., Rademakers R., Schellenberg G.D., Miller B.L., Mandelkow E., Geschwind D.H. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum. Mol. Genet. 2012, 21:3500-3512.
6. Covy J.P., Yuan W., Waxman E.A., Hurtig H.I., Van Deerlin V.M., Giasson B.I. Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations. Move. Disord. 2009, 24:32-39.
7. Cruchaga C., Haller G., Chakraverty S., Mayo K., Vallania F.L., Mitra R.D., Faber K., Williamson J., Bird T., Diaz-Arrastia R., Foroud T.M., Boeve B.F., Graff-Radford N.R., St Jean P., Lawson M., Ehm M.G., Mayeux R., Goate A.M. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One 2012, 7:e31039. Consortium, N.-L.N.F.S.
8. Dachsel J.C., Ross O.A., Mata I.F., Kachergus J., Toft M., Cannon A., Baker M., Adamson J., Hutton M., Dickson D.W., Farrer M.J. Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. Acta Neuropathol. 2007, 113:601-606.
9. de Silva R., Lashley T., Gibb G., Hanger D., Hope A., Reid A., Bandopadhyay R., Utton M., Strand C., Jowett T., Khan N., Anderton B., Wood N., Holton J., Revesz T., Lees A. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol. Appl. Neurobiol. 2003, 29:288-302.
10. Devine M.J., Lewis P.A. Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2. FEBS J. 2008, 275:5748-5757.
11. Doherty K.M., Silveira-Moriyama L., Parkkinen L., Healy D.G., Farrell M., Mencacci N.E., Ahmed Z., Brett F.M., Hardy J., Quinn N., Counihan T.J., Lynch T., Fox Z.V., Revesz T., Lees A.J., Holton J.L. Parkin disease: a clinicopathologic entity?. JAMA Neurol. 2013, 70:1-9.
12. Gaig C., Ezquerra M., Marti M.J., Valldeoriola F., Munoz E., Llado A., Rey M.J., Cardozo A., Molinuevo J.L., Tolosa E. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J.Neurol. Sci. 2008, 270:94-98.
13. Gan-Or Z., Bar-Shira A., Mirelman A., Gurevich T., Giladi N., Orr-Urtreger A. The age at motor symptoms onset in LRRK2-associated Parkinson's disease is affected by a variation in the MAPT locus: a possible interaction. J.Mol. Neurosci. 2012, 46:541-544.
14. Giasson B.I., Covy J.P., Bonini N.M., Hurtig H.I., Farrer M.J., Trojanowski J.Q., Van Deerlin V.M. Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 2006, 59:315-322.
15. Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A., Lees A.J., Shaw K., Bhatia K.P., Bonifati V., Quinn N.P., Lynch J., Healy D.G., Holton J.L., Revesz T., Wood N.W. Acommon LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005, 365:415-416.
16. Goldwurm S., Tunesi S., Tesei S., Zini M., Sironi F., Primignani P., Magnani C., Pezzoli G. Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease. Move. Disord. 2011, 26:2144-2145.
17. Hasegawa K., Kowa H. Autosomal dominant familial Parkinson disease: older onset of age, and good response to levodopa therapy. Eur. Neurol. 1997, 38(suppl 1):39-43.
18. Hasegawa K., Stoessl A.J., Yokoyama T., Kowa H., Wszolek Z.K., Yagishita S. Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat. Disord. 2009, 15:300-306.
19. Hasegawa M., Arai T., Akiyama H., Nonaka T., Mori H., Hashimoto T., Yamazaki M., Oyanagi K. TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 2007, 130:1386-1394.
20. Hayesmoore J.B., Bray N.J., Cross W.C., Owen M.J., O'Donovan M.C., Morris H.R. The effect of age and the H1c MAPT haplotype on MAPT expression in human brain. Neurobiol. Aging 2009, 30:1652-1656.
21. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., Brice A., Aasly J., Zabetian C.P., Goldwurm S., Ferreira J.J., Tolosa E., Kay D.M., Klein C., Williams D.R., Marras C., Lang A.E., Wszolek Z.K., Berciano J., Schapira A.H., Lynch T., Bhatia K.P., Gasser T., Lees A.J., Wood N.W. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008, 7:583-590.
22. Hyman B.T., Phelps C.H., Beach T.G., Bigio E.H., Cairns N.J., Carrillo M.C., Dickson D.W., Duyckaerts C., Frosch M.P., Masliah E., Mirra S.S., Nelson P.T., Schneider J.A., Thal D.R., Thies B., Trojanowski J.Q., Vinters H.V., Montine T.J. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012, 8:1-13.
23. Hyman B.T., Trojanowski J.Q. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J.Neuropathol. Exp. Neurol. 1997, 56:1095-1097.
24. Jin S.C., Pastor P., Cooper B., Cervantes S., Benitez B.A., Razquin C., Goate A., Cruchaga C. Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort. Alzheimers Res. Ther. 2012, 4:34.
25. Josephs K.A., Whitwell J.L., Knopman D.S., Hu W.T., Stroh D.A., Baker M., Rademakers R., Boeve B.F., Parisi J.E., Smith G.E., Ivnik R.J., Petersen R.C., Jack C.R., Dickson D.W. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 2008, 70:1850-1857.
26. Kara E., Ling H., Pittman A.M., Shaw K., de Silva R., Simone R., Holton J.L., Warren J.D., Rohrer J.D., Xiromerisiou G., Lees A., Hardy J., Houlden H., Revesz T. The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. Neurobiol. Aging 2012, 33:2231.e7-2231.e14.
27. Khan N.L., Jain S., Lynch J.M., Pavese N., Abou-Sleiman P., Holton J.L., Healy D.G., Gilks W.P., Sweeney M.G., Ganguly M., Gibbons V., Gandhi S., Vaughan J., Eunson L.H., Katzenschlager R., Gayton J., Lennox G., Revesz T., Nicholl D., Bhatia K.P., Quinn N., Brooks D., Lees A.J., Davis M.B., Piccini P., Singleton A.B., Wood N.W. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005, 128:2786-2796.
28. King A., Al-Sarraj S., Troakes C., Smith B.N., Maekawa S., Iovino M., Spillantini M.G., Shaw C.E. Mixed tau, TDP-43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant. Acta Neuropathol. 2013, 125:303-310.
29. King A., Sweeney F., Bodi I., Troakes C., Maekawa S., Al-Sarraj S. Abnormal TDP-43 expression is identified in the neocortex in cases of dementia pugilistica, but is mainly confined to the limbic system when identified in high and moderate stages of Alzheimer's disease. Neuropathology 2010, 30:408-419.
30. Lashley T., Holton J.L., Revesz T. TDP-43 pathology may occur in the BRI2 gene-related dementias. Acta Neuropathol. 2011, 121:559-560.
31. Mackenzie I.R., Rademakers R., Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010, 9:995-1007.
32. McKee A.C., Stein T.D., Nowinski C.J., Stern R.A., Daneshvar D.H., Alvarez V.E., Lee H.S., Hall G., Wojtowicz S.M., Baugh C.M., Riley D.O., Kubilus C.A., Cormier K.A., Jacobs M.A., Martin B.R., Abraham C.R., Ikezu T., Reichard R.R., Wolozin B.L., Budson A.E., Goldstein L.E., Kowall N.W., Cantu R.C. Thespectrum of disease in chronic traumatic encephalopathy. Brain 2013, 136:43-64.
33. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
34. Morales R., Green K.M., Soto C. Cross currents in protein misfolding disorders: interactions and therapy. CNS Neurol. Disord. Drug Targets 2009, 8:363-371.
35. Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W., Kretzschmar H.A., Trojanowski J.Q., Lee V.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
36. Rajput A., Dickson D.W., Robinson C.A., Ross O.A., Dachsel J.C., Lincoln S.J., Cobb S.A., Rajput M.L., Farrer M.J. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 2006, 67:1506-1508.
37. Santpere G., Ferrer I. LRRK2 and neurodegeneration. Acta Neuropathol. 2009, 117:227-246.
38. Sierra M., Gonzalez-Aramburu I., Sanchez-Juan P., Sanchez-Quintana C., Polo J.M., Berciano J., Combarros O., Infante J. High frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in Cantabria (Spain). Move. Disord. 2011, 26:2343-2346.
39. Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., Baralle F., de Belleroche J., Mitchell J.D., Leigh P.N., Al-Chalabi A., Miller C.C., Nicholson G., Shaw C.E. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672.
40. Thal D.R., Rub U., Orantes M., Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
41. Uryu K., Nakashima-Yasuda H., Forman M.S., Kwong L.K., Clark C.M., Grossman M., Miller B.L., Kretzschmar H.A., Lee V.M., Trojanowski J.Q., Neumann M. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J.Neuropathol. Exp. Neurol. 2008, 67:555-564.
42. Wider C., Dickson D.W., Wszolek Z.K. Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener. Dis. 2010, 7:175-179.
43. Wszolek Z.K., Pfeiffer R.F., Tsuboi Y., Uitti R.J., McComb R.D., Stoessl A.J., Strongosky A.J., Zimprich A., Muller-Myhsok B., Farrer M.J., Gasser T., Calne D.B., Dickson D.W. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004, 62:1619-1622.
44. Wszolek Z.K., Vieregge P., Uitti R.J., Gasser T., Yasuhara O., McGeer P., Berry K., Calne D.B., Vingerhoets F.J., Klein C., Pfeiffer R.F. German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia-longitudinal observations. Parkinsonism Relat. Disord. 1997, 3:125-139.
45. Xiromerisiou G., Houlden H., Sailer A., Silveira-Moriyama L., Hardy J., Lees A.J. Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease. Move. Disord. 2012, 27:1323.
46. Yokota O., Davidson Y., Bigio E.H., Ishizu H., Terada S., Arai T., Hasegawa M., Akiyama H., Sikkink S., Pickering-Brown S., Mann D.M. Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta neuropathologica 2010, 120:55-66. http://dx.doi.org/10.1007/s00401-010-0702-1.
47. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.